Lipopolysaccharide binding protein is associated with CVD risk in older adults

Lisa M Roberts1,2, Thomas W Buford3,4,5

  • 1Department of Medicine, Division of Gerontology/Geriatrics/Palliative Care, University of Alabama At Birmingham, 1313 13th Street S., Birmingham, AL, USA.

Insights

Higher levels of lipopolysaccharide binding protein (LBP) are linked to lower cardiovascular disease (CVD) risk in older adults. This suggests LBP may play a role in mitigating CVD risk factors.

Area of Science:

  • Gerontology
  • Cardiovascular Medicine
  • Microbiome Research

Background:

  • Gut permeability is a potential contributor to cardiovascular disease (CVD) risk.
  • Biomarkers for gut permeability and their association with CVD risk, especially in older adults, are not well-established.

Purpose of the Study:

  • To investigate the association between serum biomarkers of gut permeability and bacterial toxin clearance and CVD risk in older adults.
  • Specifically examined intestinal fatty acid-binding protein (iFABP), cluster of differentiation 14 (CD14), and lipopolysaccharide binding protein (LBP).

Main Methods:

  • Cross-sectional study of 74 older adults (mean age 69.6 years) stratified by CVD risk.
  • One-way ANOVAs and Pearson correlations were used to analyze biomarker differences and associations with CVD risk scores.

Main Results:

  • Lipopolysaccharide binding protein (LBP) levels differed significantly across CVD risk categories, being higher in moderate and high-moderate risk groups compared to the high-risk group.
  • LBP showed a moderate negative correlation with age and systolic blood pressure, and a small positive correlation with total and LDL cholesterol.
  • Intestinal fatty acid-binding protein (iFABP) and cluster of differentiation 14 (CD14) did not show significant differences between risk categories.

Conclusions:

  • Higher circulating LBP concentrations are associated with lower CVD risk in older adults.
  • Lower iFABP and reduced systemic inflammation were also linked to lower CVD risk.
  • These findings suggest LBP may be a significant factor in reducing CVD risk among the elderly.
Abstract

Related Concept Videos

Formation of Lipopolysaccharides01:19

Formation of Lipopolysaccharides

Lipopolysaccharides (LPS) are crucial components of the outer membrane of Gram-negative bacteria, serving both structural and functional roles. It contributes to membrane stability and protects bacteria from host immune responses. LPS is composed of three major regions—lipid A, a core oligosaccharide, and an O antigen. The biosynthesis and assembly of LPS involve a highly coordinated set of enzymatic reactions and transport mechanisms. Additionally, LPS is recognized as an endotoxin,...
323
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
403
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
475
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
226
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
721
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
560